Liora Michal Schultz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liora Michal Schultz has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Crystal L. Mackall
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
36 shared publications - Kara L. Davis
Stanford University
26 shared publications - Sneha Ramakrishna
Stanford University
26 shared publications - Agnes Reschke
Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California
25 shared publications - Alexandria Mary Jensen
Stanford University, Stanford, California, United States
25 shared publications - Anne Marijn Kramer
Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, California
25 shared publications
Latest Publications
- 28 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70786
Venetoclax as Salvage Treatment for Relapsed/Refractory B‐ALL Post‐CAR‐T Therapy
Background: Despite high early response rates following chimeric antigen receptor T‐cell therapy (CAR‐T) for relapsed/refractory pediatric B‐cell acute lymphoblastic leukemia (B‐ALL), many patients relapse, and downregulation of the antigen targeted by the CAR‐T has emerged as a major challenge. Furthermore, minimal residual disease (MRD) screening using next‐generation sequencing (NGS) does not inform antigen status. In cases of either antigen downregulation or unknown antigen status, there is a need for antigen‐agnostic salvage agents such as venetoclax. Data regarding venetoclax use in the post‐CAR‐T setting, however, remain limited. Procedure: We conducted a retrospective study of patients with B‐ALL who received CAR‐T therapy followed by venetoclax from nine tertiary pediatric oncology centers in the United States. Results: Nineteen patients received venetoclax for treatment of relapsed/refractory (R/R) B‐ALL following CAR‐T therapy. The median number of relapses pre‐venetoclax was 2 (range, 1–5). Of 12 patients with known antigen expression status at venetoclax initiation, 11 (92%) had antigen downregulation. Side effects of venetoclax monotherapy were nausea (100%) and rash (25%); in combination chemotherapy, cytopenias (63%) and infections (42%) were also reported. No patient deaths occurred from venetoclax toxicity. After venetoclax, 8 of 19 patients (42%) achieved either morphologic complete remission (CR) or clearance of prior MRD. Of 11 patients with baseline MRD‐only disease, 4 (36%) achieved MRD negativity. Of 8 patients with baseline morphologic disease, 2 (25%) achieved morphologic CR. Patients with antigen downregulation had a 29% morphologic CR rate. Conclusions: Our experience suggests tolerability and promise of venetoclax in pediatric R/R B‐ALL, including patients with antigen downregulation.
- 28 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70786
Venetoclax as Salvage Treatment for Relapsed/Refractory B‐ALL Post‐CAR‐T Therapy
Background: Despite high early response rates following chimeric antigen receptor T‐cell therapy (CAR‐T) for relapsed/refractory pediatric B‐cell acute lymphoblastic leukemia (B‐ALL), many patients relapse, and downregulation of the antigen targeted by the CAR‐T has emerged as a major challenge. Furthermore, minimal residual disease (MRD) screening using next‐generation sequencing (NGS) does not inform antigen status. In cases of either antigen downregulation or unknown antigen status, there is a need for antigen‐agnostic salvage agents such as venetoclax. Data regarding venetoclax use in the post‐CAR‐T setting, however, remain limited. Procedure: We conducted a retrospective study of patients with B‐ALL who received CAR‐T therapy followed by venetoclax from nine tertiary pediatric oncology centers in the United States. Results: Nineteen patients received venetoclax for treatment of relapsed/refractory (R/R) B‐ALL following CAR‐T therapy. The median number of relapses pre‐venetoclax was 2 (range, 1–5). Of 12 patients with known antigen expression status at venetoclax initiation, 11 (92%) had antigen downregulation. Side effects of venetoclax monotherapy were nausea (100%) and rash (25%); in combination chemotherapy, cytopenias (63%) and infections (42%) were also reported. No patient deaths occurred from venetoclax toxicity. After venetoclax, 8 of 19 patients (42%) achieved either morphologic complete remission (CR) or clearance of prior MRD. Of 11 patients with baseline MRD‐only disease, 4 (36%) achieved MRD negativity. Of 8 patients with baseline morphologic disease, 2 (25%) achieved morphologic CR. Patients with antigen downregulation had a 29% morphologic CR rate. Conclusions: Our experience suggests tolerability and promise of venetoclax in pediatric R/R B‐ALL, including patients with antigen downregulation.
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7115-7124
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults
Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.
- 16 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7115-7124
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults
Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.
- 24 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6422-6434
HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.
- 24 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6422-6434
HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL
We previously reported poor long-term outcomes in patients with B-acute lymphoblastic leukemia (B-ALL) who developed hemophagocytic lymphohistiocytosis (HLH)–like toxicities (HLH-LT) after treatment with tisagenlecleucel. Since then, a consensus definition, immune effector cell–associated HLH-like syndrome (IEC-HS), was developed. Here, we report results from a multicenter retrospective study of children and young adults with B-ALL treated with tisagenlecleucel between 2018 and 2023, describing the incidence, diagnostic overlap, clinical phenotypes, and associated long-term outcomes of HLH-like syndromes. Of 154 tisagenlecleucel recipients, 14.9% met IEC-HS criteria, 21.4% met HLH-LT criteria, and 13% were identified as having HLH by treating institutions in the electronic health record; 10% met all definitions. Each HLH-like syndrome was associated with shortened overall survival and event-free survival, adjusting for baseline disease burden (P< .0001). Those with any HLH-like syndrome experienced 1-year cumulative incidence of nonresponse/relapse of 60% (95% confidence interval [CI], 43.1-76.9) vs 28.2% (95% CI, 20.0-36.5), P< .001, and nonrelapse mortality of 11.4% (95% CI, 0.7-22.1) vs 0% (95% CI, 0-0), P< .001, compared with those without. In those with high disease burden, patients with any HLH-like syndrome had a 1-year cumulative incidence of CD19− relapse of 65.2% (95% CI, 44.7-85.8) vs 2% (95% CI, 0-6.4) in those with no HLH-like syndrome, P< .001. Furthermore, adjusting for disease burden, any HLH-like syndrome was independently predictive of CD19− relapse with a hazard ratio of 8.10 (95% CI, 3.6-18.4), P< .001. These findings demonstrate partial definitional overlap of HLH-like syndromes and the prognostic significance of IEC-HS and identify CD19− relapse and nonrelapse mortality as key outcome drivers.
- Open Access
- 4 August 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (4)
Tracking B-cell depletion and reconstitution using next-generation immunosequencing
- 4 August 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (4)
Open AccessTracking B-cell depletion and reconstitution using next-generation immunosequencing
- Open Access
- 12 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 3281-3289
Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia
Determination of measurable residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) using next-generation immunosequencing (clonoSEQ; Adaptive Biotechnologies) has emerged as an essential and sensitive tool. The clonoSEQ assay identifies and tracks all the B-cell and T-cell receptor rearrangements present in a sample. With widening clinical use of immunosequencing for MRD monitoring (next-generation sequencing [NGS]-MRD), clinicians are increasingly encountering cases with results that are considered to be inconclusive, where immunosequencing yields detectable clonotypic sequences, yet it is unclear whether they indicate ALL, normal background, or an independent etiology. There is a need for guidance in the clinical interpretation of immunosequencing results. In this article, we describe various features of immunosequencing reporting and their clinical implications through a series of illustrative clinical cases. Each case presents a distinct scenario encountered in the clinical setting where NGS-MRD had varying clinical implications. Through aggregate evaluation of the various components of the results, such as the sequence locus, sequence abundance, clonal tracking, and levels of detection and blank, we formulate systematic interpretative tools that can be leveraged to inform clinical decision-making. The goal of this article is to serve as a useful guide for clinicians as they interpret immunosequencing results for pediatric ALL.
- 12 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 3281-3289
Open AccessInterpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia
Determination of measurable residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) using next-generation immunosequencing (clonoSEQ; Adaptive Biotechnologies) has emerged as an essential and sensitive tool. The clonoSEQ assay identifies and tracks all the B-cell and T-cell receptor rearrangements present in a sample. With widening clinical use of immunosequencing for MRD monitoring (next-generation sequencing [NGS]-MRD), clinicians are increasingly encountering cases with results that are considered to be inconclusive, where immunosequencing yields detectable clonotypic sequences, yet it is unclear whether they indicate ALL, normal background, or an independent etiology. There is a need for guidance in the clinical interpretation of immunosequencing results. In this article, we describe various features of immunosequencing reporting and their clinical implications through a series of illustrative clinical cases. Each case presents a distinct scenario encountered in the clinical setting where NGS-MRD had varying clinical implications. Through aggregate evaluation of the various components of the results, such as the sequence locus, sequence abundance, clonal tracking, and levels of detection and blank, we formulate systematic interpretative tools that can be leveraged to inform clinical decision-making. The goal of this article is to serve as a useful guide for clinicians as they interpret immunosequencing results for pediatric ALL.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 13 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 13 shows ROC curves for the two cytokine signature at D14 and D21
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 1 shows individual lab values over time for grade 2+ IECHS
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr2+ CRS.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Clinical manifestations of gr2+ CRS.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 5 shows cellular composition of apheresis material (A) and infused products (B) by IECHS severity.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Supplemental Figure 8 shows the individual laboratory and CAR T values for the patient with severe IECHS who underwent daily cytokine profiling.